SCHEMBL2647231

SCHEMBL2647231

C=CC(O)c1c(C(C)C)nc(C(C)C)c(CCCCC)c1-c1ccc(F)cc1

nearest known ligand 0.78

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GCGR P47871 20/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2662983 1.00 GCGR (0.78) GCGR
SCHEMBL2647383 0.88 GCGR (0.76) GCGR
SCHEMBL2650283 0.88 GCGR (0.76) GCGR
SCHEMBL2647341 0.88 GCGR (1.00) GCGR
SCHEMBL2662977 0.88 GCGR (1.00) GCGR
SCHEMBL2649472 0.87 GCGR (0.81) GCGR
SCHEMBL2662985 0.87 GCGR (0.74) GCGR
SCHEMBL2647605 0.86 GCGR (1.00) GCGR
SCHEMBL2650496 0.86 GCGR (0.84) GCGR
SCHEMBL2648218 0.85 GCGR (0.83) GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218431-B1 GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES BAYER CORPORATION 2001-04-17 US disclosed